4(R)-t-butoxycarbonyl-4-aminobutyric acid methyl ester

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4(R)-t-butoxycarbonyl-4-aminobutyric acid methyl ester
• 英文别名: α-tert-butyl γ-methyl glutamate；1-Tert-butyl 5-methyl 2-aminopentanedioate；1-O-tert-butyl 5-O-methyl 2-aminopentanedioate
• 化学式: C₁₀H₁₉NO₄
• 分子量: 217.265
• InChiKey: QSAXGMMUKHMOBI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  15
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  78.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4(R)-t-butoxycarbonyl-4-aminobutyric acid methyl ester 在 lithium cyclohexylisopropylamide 、 三乙胺 作用下， 以 正己烷 为溶剂， 生成 t-butyl 2-tritylamino-4-carbomethoxy-5-hydroxy-5-phenyl-(2RS)-pentanoate
  参考文献：
  名称：

  立体特异性氨基酸合成；谷氨酸衍生的γ-阴离子的制备

  摘要：

  α-叔丁基γ-甲基N-三苯甲基-L-谷氨酸盐（7）与异丙基环己基锂锂在己烷中的反应导致γ-酯烯醇化物的特定形成，这是立体定向α的γ-阴离子合成子的潜在合成等价物-氨基酸合成。

  DOI：

  10.1039/c39880000828
• 作为产物：
  描述：

  1-(tert-butyl) 5-methyl 2-[(diphenylmethylene)amino]pentanedioate 在 柠檬酸 作用下， 以 四氢呋喃 为溶剂， 生成 4(R)-t-butoxycarbonyl-4-aminobutyric acid methyl ester
  参考文献：
  名称：

  Enantiomeric enrichment of α-amino acid derivatives: recrystallization of N-Fmoc α-amino acid tert-butyl esters

  摘要：

  The optical purity of products derived from enantioselective reactions of the benzophenone imine of glycine tert-butyl esters can often be improved by conversion to the N-Fmoc alpha -amino acid tert-butyl esters followed by simple recrystallization. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(01)00554-3

文献信息

• [EN] PCSK9 ANTAGONIST COMPOUNDS<br/>[FR] COMPOSÉS ANTAGONISTES DU PCSK
  申请人：MERCK SHARP & DOHME

  公开号：WO2021127460A1

  公开（公告）日：2021-06-24

  Disclosed are compounds of Formula (I), or a pharmaceutically acceptable salt thereof: (I) wherein A, A1, A2, R1, R2 and R3 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.

  揭示了化合物的结构式（I），或其药用盐：（I）其中A，A1，A2，R1，R2和R3如本文所定义，这些化合物具有拮抗PCSK9的属性。还描述了包含结构式I的化合物或其盐的制药配方，以及治疗心血管疾病和与PCSK9活性相关的疾病的方法，例如动脉粥样硬化，高胆固醇血症，冠心病，代谢综合征，急性冠状综合征或相关心血管疾病和心脏代谢疾病的条件。
• Highly enantioselective synthesis of cyclic and functionalized α-amino acids by means of a chiral phase transfer catalyst
  作者：E.J Corey、Mark C Noe、Feng Xu

  DOI：10.1016/s0040-4039(98)01067-3

  日期：1998.7

  The chiral quaternary ammonium salt 1 serves as phase transfer catalyst for the enantioselective conversion of the glycine derivative 2 to a variety of cyclic and acyclic chiral α-amino acids with enantioselectivities as high as 200:1 in alkylation and Michael addition reactions.

  手性季铵盐1充当相转移催化剂，用于在烷基化和迈克尔加成反应中将甘氨酸衍生物2对映选择性转化为对映选择性高达200：1的各种环状和无环手性α-氨基酸。
• [EN] PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING<br/>[FR] CONJUGUÉS LIGAND DE LIAISON À UN ANTIGÈNE DE MEMBRANE SPÉCIFIQUE À LA PROSTATE (PSMA) LIEUR ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：PURDUE RESEARCH FOUNDATION

  公开号：WO2011106639A1

  公开（公告）日：2011-09-01

  Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical compositions containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.

  本文描述了前列腺特异性膜抗原（PSMA）结合偶联物，可用于传递治疗、诊断和成像试剂。还描述了含有它们的制药组合物以及使用偶联物和组合物的方法。还描述了制造偶联物和含有它们的组合物的过程。
• Synthesis and Purification of Pteroic Acid and Conjugates Thereof
  申请人：Xu Le-Cun

  公开号：US20080207625A1

  公开（公告）日：2008-08-28

  Methods for purifying pteroic acid, analogs of pteroic acid, and derivatives of pteroic acid are described. Methods for synthesizing and purifying conjugates of vitamins, including FITC conjugates of folic acid, folic acid analogs, and derivatives of folic acid and folic acid analogs are also described. Purified forms of pteroic acid, derivatives and analogs of pteroic acid, and conjugates thereof are also described.

  本文描述了纯化叶酸、叶酸类似物和叶酸衍生物的方法。还描述了合成和纯化维生素共轭物的方法，包括荧光素同型半胱氨酸（FITC）共轭的叶酸、叶酸类似物和叶酸衍生物。还描述了纯化的叶酸、叶酸衍生物和类似物以及它们的共轭物。
• AMINOBUTANOIC ACID DERIVATIVES
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1024134A1

  公开（公告）日：2000-08-02

  An aminobutyric acid derivative of the formula (I): (wherein all symbols are as defined in the specification) and salt thereof. salt thereof. The compounds of the formula (I) possess an inhibitory activity on matrix metalloproteinase and are useful for prevention and / or treatment of diseases, for example, rheumatoid diseases, arthrosteitis, unusual bone resorption, osteoporosis, periodontitis, interstitial nephritis, arteriosclerosis, pulmonary emphysema, cirrhosis, cornea injury, metastasis of, invasion of or growth of tumor cells, autoimmune disease (e.g. Crohn's disease, Sjogren's syndrome), disease caused by vascular emigration or infiltration of leukocytes, arterialization, multiple sclerosis, aorta aneurysm, endometriosis.

  式（I）的氨基丁酸衍生物： (其中所有符号如说明书中所定义）及其盐。 式（I）化合物对基质金属蛋白酶具有抑制活性，可用于预防和/或治疗疾病，例如类风湿病、关节炎、异常骨吸收、骨质疏松症、牙周炎、间质性肾炎、动脉硬化、肺气肿、肝硬化、角膜损伤、肿瘤细胞的转移、侵入或生长、自身免疫性疾病（如克罗恩病、Sj.如克罗恩病、Sjogren 综合症）、血管移位或白细胞浸润引起的疾病、动脉化、多发性硬化、主动脉瘤、子宫内膜异位症。